Lagevrio to Get 8.2% Price Cut in July, 2.7% for Kerendia: CEA

MSD’s oral COVID-19 pill Lagevrio (molnupiravir) and Bayer Yakuhin’s chronic kidney disease (CKD) therapy Kerendia (finerenone) are braced for price reductions under the cost-effectiveness assessment (CEA) scheme, effective July 1. The Central Social Insurance Medical Council, a reimbursement policy panel...read more